Cargando…

Gene/Cell Therapy Approaches for Immune Dysregulation Polyendocrinopathy Enteropathy X-Linked Syndrome

Immune dysregulation, Polyendocrinopathy, Enteropathy, X-linked (IPEX) syndrome is a rare autoimmune disease due to mutations in the gene encoding for Forkhead box P3 (FOXP3), a transcription factor fundamental for the function of thymus-derived (t) regulatory T (Treg) cells. The dysfunction of Treg...

Descripción completa

Detalles Bibliográficos
Autores principales: Passerini, Laura, Santoni de Sio, Francesca R., Porteus, Matthew H., Bacchetta, Rosa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4443799/
https://www.ncbi.nlm.nih.gov/pubmed/25274247
http://dx.doi.org/10.2174/1566523214666141001123828
_version_ 1782373057410629632
author Passerini, Laura
Santoni de Sio, Francesca R.
Porteus, Matthew H.
Bacchetta, Rosa
author_facet Passerini, Laura
Santoni de Sio, Francesca R.
Porteus, Matthew H.
Bacchetta, Rosa
author_sort Passerini, Laura
collection PubMed
description Immune dysregulation, Polyendocrinopathy, Enteropathy, X-linked (IPEX) syndrome is a rare autoimmune disease due to mutations in the gene encoding for Forkhead box P3 (FOXP3), a transcription factor fundamental for the function of thymus-derived (t) regulatory T (Treg) cells. The dysfunction of Treg cells results in the development of devastating autoimmune manifestations affecting multiple organs, eventually leading to premature death in infants, if not promptly treated by hematopoietic stem cell transplantation (HSCT). Novel gene therapy strategies can be developed for IPEX syndrome as more definitive cure than allogeneic HSCT. Here we describe the therapeutic approaches, alternative to HSCT, currently under development. We described that effector T cells can be converted in regulatory T cells by LV-mediated FOXP3-gene transfer in differentiated T lymphocytes. Despite FOXP3 mutations mainly affect a highly specific T cell subset, manipulation of stem cells could be required for long-term remission of the disease. Therefore, we believe that a more comprehensive strategy should aim at correcting FOXP3-mutated stem cells. Potentials and hurdles of both strategies will be highlighted here.
format Online
Article
Text
id pubmed-4443799
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Bentham Science Publishers
record_format MEDLINE/PubMed
spelling pubmed-44437992015-05-28 Gene/Cell Therapy Approaches for Immune Dysregulation Polyendocrinopathy Enteropathy X-Linked Syndrome Passerini, Laura Santoni de Sio, Francesca R. Porteus, Matthew H. Bacchetta, Rosa Curr Gene Ther Article Immune dysregulation, Polyendocrinopathy, Enteropathy, X-linked (IPEX) syndrome is a rare autoimmune disease due to mutations in the gene encoding for Forkhead box P3 (FOXP3), a transcription factor fundamental for the function of thymus-derived (t) regulatory T (Treg) cells. The dysfunction of Treg cells results in the development of devastating autoimmune manifestations affecting multiple organs, eventually leading to premature death in infants, if not promptly treated by hematopoietic stem cell transplantation (HSCT). Novel gene therapy strategies can be developed for IPEX syndrome as more definitive cure than allogeneic HSCT. Here we describe the therapeutic approaches, alternative to HSCT, currently under development. We described that effector T cells can be converted in regulatory T cells by LV-mediated FOXP3-gene transfer in differentiated T lymphocytes. Despite FOXP3 mutations mainly affect a highly specific T cell subset, manipulation of stem cells could be required for long-term remission of the disease. Therefore, we believe that a more comprehensive strategy should aim at correcting FOXP3-mutated stem cells. Potentials and hurdles of both strategies will be highlighted here. Bentham Science Publishers 2014-12 2014-12 /pmc/articles/PMC4443799/ /pubmed/25274247 http://dx.doi.org/10.2174/1566523214666141001123828 Text en © 2014 Bentham Science Publishers http://creativecommons.org/licenses/by-nc/3.0/ This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
spellingShingle Article
Passerini, Laura
Santoni de Sio, Francesca R.
Porteus, Matthew H.
Bacchetta, Rosa
Gene/Cell Therapy Approaches for Immune Dysregulation Polyendocrinopathy Enteropathy X-Linked Syndrome
title Gene/Cell Therapy Approaches for Immune Dysregulation Polyendocrinopathy Enteropathy X-Linked Syndrome
title_full Gene/Cell Therapy Approaches for Immune Dysregulation Polyendocrinopathy Enteropathy X-Linked Syndrome
title_fullStr Gene/Cell Therapy Approaches for Immune Dysregulation Polyendocrinopathy Enteropathy X-Linked Syndrome
title_full_unstemmed Gene/Cell Therapy Approaches for Immune Dysregulation Polyendocrinopathy Enteropathy X-Linked Syndrome
title_short Gene/Cell Therapy Approaches for Immune Dysregulation Polyendocrinopathy Enteropathy X-Linked Syndrome
title_sort gene/cell therapy approaches for immune dysregulation polyendocrinopathy enteropathy x-linked syndrome
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4443799/
https://www.ncbi.nlm.nih.gov/pubmed/25274247
http://dx.doi.org/10.2174/1566523214666141001123828
work_keys_str_mv AT passerinilaura genecelltherapyapproachesforimmunedysregulationpolyendocrinopathyenteropathyxlinkedsyndrome
AT santonidesiofrancescar genecelltherapyapproachesforimmunedysregulationpolyendocrinopathyenteropathyxlinkedsyndrome
AT porteusmatthewh genecelltherapyapproachesforimmunedysregulationpolyendocrinopathyenteropathyxlinkedsyndrome
AT bacchettarosa genecelltherapyapproachesforimmunedysregulationpolyendocrinopathyenteropathyxlinkedsyndrome